Global Health Briefing: Drug Access, NHS Cuts, and Medical Research Updates
A cross-border investigation by DW and ICIJ found that pricing and patent structures for cancer drug Keytruda have limited global patient access despite its commercial success. In the UK, NHS trusts plan to cut approximately 21,000 jobs by 2028 amid budget pressures, while private firms providing NHS services recorded £1.6 billion in profits over two years. Additional health stories span tuberculosis drug research, assisted dying legislation, hospital reform directives in India, and public health misinformation.
Progressive outlets frame NHS privatisation profits as evidence of systemic exploitation of a public health service, and highlight that Keytruda's pricing model prioritises pharmaceutical revenue over equitable patient access globally.
Documented reporting confirms that NHS trusts are reducing workforces due to budget constraints, private NHS contractors earned £1.6 billion in profit on £12 billion in contracts, and Keytruda's global access gap is tied to patent and pricing structures identified by an international investigative consortium.
Conservative outlets may frame NHS private sector involvement as a necessary efficiency measure to manage public health costs, and view patent protections for drugs like Keytruda as legitimate incentives for pharmaceutical innovation and research investment.
Documented reporting confirms that NHS trusts are reducing workforces due to budget constraints, private NHS contractors earned £1.6 billion in profit on £12 billion in contracts, and Keytruda's global access gap is tied to patent and pricing structures identified by an international investigative consortium.
Multiple independent reports document significant structural pressures across global and UK health systems, including workforce reductions, private profit accumulation, and unequal access to high-cost medicines.